Skip to main content

Scleroderma/Raynauds

Osteitis in Systemic Sclerosis is UNCOMMON. French study of 48 pts shows 54% w/ osteitis beneath digital tip ulcers. Pain (75%), erythema (73%), warmth (73%) & 65% had high CRP. X‐ray, CT‐scans or MR. Antibiotics were 1st line therapy. https://t.co/o58gwq2SCC

Dr. John Cush RheumNow ( View Tweet)

Jan 23, 2021

2020 Rheumatology Year in Review

Jan 14, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article
#BestACR20Tweets RT @ATSCPAssembly : Dr. Dinesh Khanna ( @sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD.

Dr. John Cush RheumNow ( View Tweet)

Dec 26, 2020
Systemic Steroids Seldom Flare Psoriasis https://t.co/14iz3l6CNf https://t.co/eiDXmoCitj
Dr. John Cush RheumNow ( View Tweet)
Dec 11, 2020
#BestACR20Tweets RT @ejdein1 : Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mRSS at Wk24 mean difference -2.8. Ziri well-tolerated. Would be great for new drug for early SSc skin. @RheumNow. https://t.co/TOS9fp4gGK https://t.co/4SDisedzs3
Dr. John Cush RheumNow ( View Tweet)
Nov 30, 2020
#BestACR20Tweets RT @TheLancetRheum: Results of the NOVESA phase 2 trial of Ziritaxestat in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20 Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. https://t.co/GCZj64i86c https://t.co/Pd6qGEGOev
Dr. John Cush RheumNow ( View Tweet)
Nov 27, 2020
Quick Read: Systemic Sclerosis and Physical Therapy. by Dr. Sheila Marie Reyes ( @RHEUMarampa). #ACR20 https://t.co/CKhfPDhmPA https://t.co/bocUIJPBbD
Dr. John Cush RheumNow ( View Tweet)
Nov 12, 2020

Rheumatology Round-Up with Drs. Kavanaugh & Cush

Nov 10, 2020

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!


Read Article

Systemic Sclerosis and Physical Therapy

Nov 09, 2020

Systemic sclerosis (SSc) is a chronic fibrosing disease currently with no available cure. Just as pharmacologic treatment is important to control the disease or delay its progression, non-pharmacologic interventions are also essential in the management of patients. 



This article will

Read Article
Results of the NOVESA phase 2 trial of Ziritaxestat (an autotaxin inhibitor) in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20 Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. 31/33 patients continue in OLE https://t.co/kVQWN1s8Zy
The Lancet Rheumatology TheLancetRheum ( View Tweet)
Nov 09, 2020
Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mRSS at Wk24 mean difference -2.8. Ziri well-tolerated. Would be great for new drug for early SSc skin. @RheumNow. https://t.co/qpvLFsAe0x
Eric Dein ejdein1 ( View Tweet)
Nov 09, 2020
Using National Inpatient Sample (NIS) claims, SSc pts hospitalized with acute MI (AMI) had a higher unadjusted inpatient mortality rate (9.17% vs. 4.68%; p=0.001)( (aOR=2.02) #ACR20 Abstr#1390 https://t.co/qWUMkJR40d

Dr. John Cush RheumNow ( View Tweet)

Nov 08, 2020
Nintedanib in rheum ILD (RA/SSc/CTD) I appreciate the volumes might not seem like much, but: - in first 1y Rx 20% more are spared a FVC decline>10% - biggest diff in UIP-like pattern With the right patient selection, nintedanib does have its place! #ACR20 ABST1048/1049 @RheumNow https://t.co/jGZdR84bBU
David Liew drdavidliew ( View Tweet)
Nov 08, 2020
Racial disparity in SSc-ILD pts treated with MMF? 1️⃣Early initiation of MMF significantly slowed ⬇️ of FVC% 2️⃣No difference in MMF efficacy between African-Americans and non-AA 3️⃣AA had baseline lower FVC% @RheumNow #ACR20 Abs0929 https://t.co/rtsbe7OCvA
Robert B Chao, MD doctorRBC ( View Tweet)
Nov 07, 2020
Interesting data re HCQ decreasing new PAH in Early SSc #scleroderma Not sure I believe it. Confounding, diff subsets get #hydroxycholoroquine due to inflammatory arthritis etc. Maybe a big pragmatic RCT is warranted as PAH is lethal @RheumNow @CRASCRRheum #ACR20 abstr#925 https://t.co/Al81sMGgxI

Janet Pope Janetbirdope ( View Tweet)

Nov 07, 2020
Hydroxychloroquine may reduce rate of progression of systemic sclerosis associated pulmonary hypertension when initiated early (<18 months). Prospective, observational study. @RheumNow #ACR2020 Abs#0925 https://t.co/nj0mNAY5Pe
Robert B Chao, MD doctorRBC ( View Tweet)
Nov 07, 2020
Please join #ACR20 for late breaking abstract on Ziritaxestat, selective autotaxin inhibitor. Phase 2a trial with stats significant effect on skin score and well tolerated. @UMIntMed Session Date Monday, November 9 Presentation Time: 12:15 PM - 12:30 PM ET

Dr. Dinesh Khanna sclerodermaUM ( View Tweet)

Nov 06, 2020
ILD in SSc has grave consequences. Abstr#393 Claims database in Ontario shows relevant Scleroderma ILD occurred in 17% of >3000 pts with nearly double the mortality #ACR20 @RheumNow @CRASCRRheum #bestinclass https://t.co/K3UXvuxBcp
Janet Pope Janetbirdope ( View Tweet)
Nov 06, 2020
Dr. Dinesh Khanna (@sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD. #ATS2020 #MiniSymposia @UMIntMed 10/

ATS Clinical Problems Assembly ATSCPAssembly ( View Tweet)

Nov 05, 2020

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Oct 29, 2020

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article

Abatacept in Early Systemic Sclerosis (ASSET study)

Oct 29, 2020

An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).



ASSET was

Read Article

FDA Invites Patient Input on Systemic Sclerosis Drug Development

Oct 28, 2020

While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug

Read Article
NEW RESEARCH: Abatacept in the treatment of diffuse cutaneous #SystemicSclerosis; clinically meaningful improvements in mRSS and other outcome measures were observed when patients transitioned to open-label #abatacept treatment https://t.co/tDSo3u8hAY #LancetRheumatology https://t.co/Nc8XYc1URW
The Lancet Rheumatology TheLancetRheum ( View Tweet)
Oct 21, 2020

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Oct 15, 2020

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article
1) If you are have diffuse scleroderma and have previously participated in a clinical trial, we need your help! You will be asked to watch video tutorial and answer a survey which will take you 20 minutes to complete. the study is supported by @WeAreSRUK @scleroderma @srfcure

Dr. Dinesh Khanna sclerodermaUM ( View Tweet)

Oct 06, 2020
×